Phase 2 study of 5'-DFUR for bladder and prostatic cancer

H. Ohmori; Y. Matsumura; J. Ochi; K. Kobashi; N. Akebi; T. Saika; K. Nanba; T. Tanahashi; T. Josen; Y. Nasu; M. Saegusa; Y. Ozaki; M. Hara; T. Asahi; N. Ike; T. Tsushima; N. Mitsuhata; T. Akagi; T. Kaeda

Phase 2 study of 5'-DFUR for bladder and prostatic cancer

H. Ohmori, Y. Matsumura, J. Ochi, K. Kobashi, N. Akebi, T. Saika, K. Nanba, T. Tanahashi, T. Josen, Y. Nasu, M. Saegusa, Y. Ozaki, M. Hara, T. Asahi, N. Ike, T. Tsushima, N. Mitsuhata, T. Akagi, T. Kaeda

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Abstract

Phase 2 study of 5'-DFUR in bladder and prostatic cancer was conducted at 15 collaborative institutions including Okayama University. 5'-DFUR was orally administered to patients at a daily dose of 800-1200 mg for more than 4 weeks. Forty-one patients with bladder cancer and 12 patients with prostatic cancer were evaluated. The response rate for bladder cancer was 31.7% (CFR, 1 case: PR, 12 cases), against no response with prostatic cancer. Moreover, the concentration of 5-FU in bladder tumors was confirmed to be high. Adverse reactions such as diarrhea, anorexia, and nausea were observed. Thus, 5'-DFUR seems to be useful for the treatment of bladder cancer.

Original language	English
Pages (from-to)	2307-2314
Number of pages	8
Journal	Japanese Journal of Cancer and Chemotherapy
Volume	18
Issue number	13
Publication status	Published - Jan 1 1991

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{9380388d6c3d48988b41f7d932f98918,

title = "Phase 2 study of 5'-DFUR for bladder and prostatic cancer",

abstract = "Phase 2 study of 5'-DFUR in bladder and prostatic cancer was conducted at 15 collaborative institutions including Okayama University. 5'-DFUR was orally administered to patients at a daily dose of 800-1200 mg for more than 4 weeks. Forty-one patients with bladder cancer and 12 patients with prostatic cancer were evaluated. The response rate for bladder cancer was 31.7% (CFR, 1 case: PR, 12 cases), against no response with prostatic cancer. Moreover, the concentration of 5-FU in bladder tumors was confirmed to be high. Adverse reactions such as diarrhea, anorexia, and nausea were observed. Thus, 5'-DFUR seems to be useful for the treatment of bladder cancer.",

author = "H. Ohmori and Y. Matsumura and J. Ochi and K. Kobashi and N. Akebi and T. Saika and K. Nanba and T. Tanahashi and T. Josen and Y. Nasu and M. Saegusa and Y. Ozaki and M. Hara and T. Asahi and N. Ike and T. Tsushima and N. Mitsuhata and T. Akagi and T. Kaeda",

year = "1991",

month = jan,

day = "1",

language = "English",

volume = "18",

pages = "2307--2314",

journal = "Japanese Journal of Cancer and Chemotherapy",

issn = "0385-0684",

publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",

number = "13",

}

TY - JOUR

T1 - Phase 2 study of 5'-DFUR for bladder and prostatic cancer

AU - Ohmori, H.

AU - Matsumura, Y.

AU - Ochi, J.

AU - Kobashi, K.

AU - Akebi, N.

AU - Saika, T.

AU - Nanba, K.

AU - Tanahashi, T.

AU - Josen, T.

AU - Nasu, Y.

AU - Saegusa, M.

AU - Ozaki, Y.

AU - Hara, M.

AU - Asahi, T.

AU - Ike, N.

AU - Tsushima, T.

AU - Mitsuhata, N.

AU - Akagi, T.

AU - Kaeda, T.

PY - 1991/1/1

Y1 - 1991/1/1

N2 - Phase 2 study of 5'-DFUR in bladder and prostatic cancer was conducted at 15 collaborative institutions including Okayama University. 5'-DFUR was orally administered to patients at a daily dose of 800-1200 mg for more than 4 weeks. Forty-one patients with bladder cancer and 12 patients with prostatic cancer were evaluated. The response rate for bladder cancer was 31.7% (CFR, 1 case: PR, 12 cases), against no response with prostatic cancer. Moreover, the concentration of 5-FU in bladder tumors was confirmed to be high. Adverse reactions such as diarrhea, anorexia, and nausea were observed. Thus, 5'-DFUR seems to be useful for the treatment of bladder cancer.

AB - Phase 2 study of 5'-DFUR in bladder and prostatic cancer was conducted at 15 collaborative institutions including Okayama University. 5'-DFUR was orally administered to patients at a daily dose of 800-1200 mg for more than 4 weeks. Forty-one patients with bladder cancer and 12 patients with prostatic cancer were evaluated. The response rate for bladder cancer was 31.7% (CFR, 1 case: PR, 12 cases), against no response with prostatic cancer. Moreover, the concentration of 5-FU in bladder tumors was confirmed to be high. Adverse reactions such as diarrhea, anorexia, and nausea were observed. Thus, 5'-DFUR seems to be useful for the treatment of bladder cancer.

UR - http://www.scopus.com/inward/record.url?scp=0025933224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025933224&partnerID=8YFLogxK

M3 - Article

C2 - 1834024

AN - SCOPUS:0025933224

VL - 18

SP - 2307

EP - 2314

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 13

ER -

Phase 2 study of 5'-DFUR for bladder and prostatic cancer

Abstract

ASJC Scopus subject areas

UN SDGs

Other files and links

Fingerprint

Cite this